SecSonar.com

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Vertex Pharmaceuticals Incorporated (VRTX) is a Biotechnology company based in US with a market capitalization of $113.6B. Revenue grew 9.6% year-over-year and the company generated $3.2B in free cash flow. This page tracks VRTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 6.1K employees · IPO Jul 24, 1991

Valuation

Valuation & price

$450.74 · as of May 13, 2026 · -14.6% vs 52w high

29.4

P/E ratio

Latest-FY diluted EPS

6.09

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$528$451$374Jul 25Dec 25Jul 26Jul 7, 25$459.41Jul 9, 25$478.97Jul 11, 25$468.85Jul 15, 25$464.20Jul 17, 25$463.27Jul 21, 25$458.49Jul 23, 25$476.95Jul 25, 25$469.65Jul 29, 25$468.41Jul 31, 25$456.87Aug 4, 25$472.27Aug 6, 25$385.65Aug 11, 25$374.46Aug 13, 25$395.92Aug 15, 25$392.79Aug 19, 25$390.76Aug 21, 25$397.46Aug 25, 25$388.94Aug 27, 25$389.08Aug 29, 25$391.02Sep 3, 25$396.62Sep 5, 25$396.12Sep 9, 25$396.48Sep 11, 25$397.37Sep 16, 25$391.36Sep 18, 25$387.11Sep 22, 25$383.13Sep 24, 25$376.62Sep 26, 25$385.74Sep 30, 25$391.64Oct 2, 25$408.85Oct 6, 25$402.90Oct 8, 25$421.15Oct 10, 25$407.79Oct 14, 25$412.22Oct 16, 25$408.61Oct 21, 25$426.27Oct 23, 25$422.63Oct 27, 25$420.17Oct 29, 25$417.21Oct 31, 25$425.57Nov 4, 25$421.67Nov 6, 25$416.25Nov 10, 25$421.20Nov 12, 25$434.19Nov 14, 25$437.15Nov 18, 25$435.52Nov 20, 25$422.32Nov 25, 25$429.82Nov 28, 25$433.61Dec 2, 25$433.15Dec 4, 25$457.36Dec 8, 25$442.04Dec 10, 25$444.64Dec 12, 25$452.04Dec 16, 25$454.96Dec 18, 25$447.38Dec 22, 25$460.31Dec 24, 25$462.99Dec 29, 25$459.78Jan 2, 26$452.13Jan 6, 26$468.38Jan 8, 26$469.68Jan 12, 26$460.59Jan 14, 26$449.53Jan 16, 26$441.36Jan 21, 26$461.14Jan 23, 26$468.41Jan 27, 26$474.17Jan 29, 26$475.68Feb 2, 26$472.01Feb 4, 26$470.52Feb 9, 26$470.87Feb 11, 26$461.24Feb 13, 26$491.47Feb 18, 26$470.31Feb 20, 26$476.90Feb 24, 26$487.43Feb 26, 26$480.13Mar 2, 26$486.03Mar 4, 26$477.89Mar 6, 26$456.69Mar 10, 26$499.17Mar 12, 26$478.13Mar 17, 26$462.49Mar 19, 26$458.05Mar 23, 26$451.24Mar 25, 26$454.97Mar 27, 26$433.07Mar 31, 26$446.54Apr 2, 26$438.71Apr 7, 26$431.86Apr 9, 26$446.78Apr 13, 26$440.05Apr 15, 26$441.70Apr 17, 26$441.20Apr 22, 26$437.67Apr 24, 26$430.29Apr 28, 26$430.14Apr 30, 26$427.38May 4, 26$429.85May 6, 26$427.65May 8, 26$429.82May 12, 26$448.29May 14, 26$450.41May 18, 26$436.58May 20, 26$430.44May 22, 26$434.52May 28, 26$447.97Jun 1, 26$438.40Jun 3, 26$428.34Jun 5, 26$446.83Jun 9, 26$445.77Jun 11, 26$445.04Jun 15, 26$450.46Jun 17, 26$458.99Jun 22, 26$466.79Jun 24, 26$475.20Jun 26, 26$491.34Jul 2, 26$528.04
$366.5452-week range$528.04
Loading valuation history…

Fundamentals

Key fundamentals

$113.6B

Market cap

9.6%

Revenue growth (YoY)

85.0%

Gross margin

$3.2B

Free cash flow (USD)

-$2.7B

Net debt

Net cash position

-0.7%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.7BFY 2017$2.5BFY 2018$3.0BFY 2019$4.2BFY 2020$6.2BFY 2021$7.6BFY 2022$8.9BFY 2023$9.9BFY 2024$11.0BFY 2025$12.1B
$1.7B$12.1B

Free cash flow by year

2016 → 2025

FY 2016$179.5MFY 2017$585.5MFY 2018$1.2BFY 2019$1.5BFY 2020$3.0BFY 2021$2.4BFY 2022$3.9BFY 2023$3.3BFY 2024$-790.3MFY 2025$3.2B
$179.5M$3.2B

Gross margin by year

2021 → 2025

FY 202188.1%FY 202287.9%FY 202387.2%FY 202486.1%FY 202585.0%
88.1%85.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

11

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $288K · 10b5-1 PlanBozic Carmen · EVP and CMO · $287.6KJun 30, 2026Filing
  • Insider sellInsider Sell $471K · 10b5-1 PlanBozic Carmen · EVP and CMO · $471.4KJun 23, 2026Filing
  • Insider sellInsider Sell $1.8M · 10b5-1 PlanBozic Carmen · EVP and CMO · $1.8MJun 17, 2026Filing
  • Insider sellInsider Sell $785K · 10b5-1 PlanBozic Carmen · EVP and CMO · $785.3KJun 9, 2026Filing
  • Insider sellInsider Sell $364K · 10b5-1 PlanLiu Joy · EVP and Chief Legal Officer · $364.2KJun 3, 2026Filing
  • Insider sellInsider Sell $888K · 10b5-1 PlanBozic Carmen · EVP and CMO · $888.3KJun 2, 2026Filing
  • Insider sellInsider Sell $614K · 10b5-1 PlanBozic Carmen · EVP and CMO · $614KMay 19, 2026Filing
  • Insider sellInsider Sell $15K · 10b5-1 PlanBunnage Mark E. · EVP, Chief Scientific Officer · $15KMay 19, 2026Filing
  • Insider sellInsider Sell $3.1M · 10b5-1 PlanBozic Carmen · EVP and CMO · $3.1MMay 14, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 13, 2026Filing

Questions

Frequently asked questions

What is Vertex Pharmaceuticals Incorporated's market cap?

Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalization of $113.6B.

What is VRTX's P/E ratio?

VRTX trades at a price-to-earnings ratio of 29.4, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is VRTX's price-to-book (P/B) ratio?

VRTX trades at 6.09 times book value per share.

Are insiders buying VRTX stock?

SEC Form 4 filings show no open-market insider buys at Vertex Pharmaceuticals Incorporated in the last 90 days (11 sells).

Same arena

Related companies in Biotechnology

REGN

Regeneron Pharmaceuticals, Inc.

$63.5B

ARGX

argenx SE

$51.7B

ALNY

Alnylam Pharmaceuticals, Inc.

$40.3B

RVMD

Revolution Medicines, Inc.

$33.3B

NVO

Novo Nordisk A/S

$202.7B

RPRX

Royalty Pharma plc

$23.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.